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Abstract
Background: Inter-a inhibitor proteins (IaIp) belong to a family of protease inhibitors that are involved in the haemostatic
and the vascular system. Dengue viruses (DENV) infections are characterized by coagulopathy and increased vascular
permeability. In this study we measured the concentration of IaIp during DENV infections and evaluated its potential as a
biomarker.
Methods and Findings: Concentrations of IaIp were measured in patients with acute DENV infections using a quantitative,
competitive enzyme linked immunoassay. Concentrations of IaIp measured in pediatric patients suffering from severe DENV
infections were significantly lower than in healthy controls.
Conclusions: This is the first report to demonstrate changes in concentration of IaIp during viral infections. The data also
highlight the potential of IaIp as a biological marker for severity of DENV infections.
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Introduction
Dengue viruses (DENV) are members of the family Flaviviridae,
genus Flavivirus, and are among the most widely distributed
arboviruses world wide that are estimated to infect more than 50
million people annually. DENV infection is usually asymptomatic
or may lead to uncomplicated ‘‘flu-like’’ disease with fever, myalgia,
arthralgia and rash. At the time of defervescence up to 5% of cases
may develop dengue hemorrhagic fever and/or dengue shock
syndrome (DHF/DSS). Mortality rates are usually around 1%.
However, during large outbreaks of DENV infections if supportive
intensive care of the patients is not applied promptly these figure can
be much higher. Although the epidemiology is changing, DHF/
DSS is still mainly a disease of children, being the leading cause of
hospitalization and death among children in South East Asia.
Inter-a inhibitor proteins (IaIp) belong to a family of structurally
related serine protease inhibitors that are naturally and abundantly
found in human plasma. The major forms in human plasma are the
inter-a inhibitor, consisting of two heavy chains and a light chain
called bikunin, and the pre-a inhibitor, consisting of one heavy
chain and a light-bikunin chain [1]. The physiological functions of
these proteins have only recently begun to be revealed. Members of
the IaIp family have been involved in physiological as well as
pathological activities such as tumor invasion, metastasis and
inflammation. For instance, bikunin has been shown to inhibit
plasmin, thereby exerting anti-inflammatory and anti-fibrinolytic
activities [2].
The potential of IaIp as a diagnostic and prognostic biomarker
as well as its therapeutic potential has been demonstrated in
bacterial sepsis [3,4]. However, the role of IaIp during viral
infections has not been investigated. In this report we describe the
plasma concentrations of IaIp in children with DENV infections
and how these concentrations correlate with disease severity.
Materials and Methods
Ethics Statement
Written informed consent for blood sampling was obtained
from all patients (their parents or legal guardians) included in the
studies described in this manuscript. The studies have been
approved by the ethics committee of the hospitals involved (Dr.
Kariadi Hospital, Semarang, Indonesia and Sophia Children’s
Hospital, Rotterdam, The Netherlands).
Children infected with DENV were selected from a longitudinal
cohort study (n= 200) conducted in Dr. Kariadi Hospital,
Semarang Indonesia [5]. Plasma samples were collected on day of
hospital admission (day 0), as well as 7 and 30 days later. Day 0 (D0)
samples were used to confirm DENV infection by a real time RT-
PCR assay. Samples from healthy individuals (n= 37) matching
demography and age of the DENV patients were used to determine
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baseline values of IaIp. These healthy control samples were
collected from healthy children that were enrolled in a prospective
cohort study (unpublished data) and resided in the same areas as the
DENV patients (Semarang, Indonesia), have the same genetic
background (Javanese, Indonesian) and matching age and gender.
No DENV-specific antibodies were detected in these samples.
Samples from 12 children infected with respiratory syncytial virus
(RSV), collected on day of admission to hospital (D0) and 30 days
later were used for comparison. The characteristics of these patients
have been described elsewhere [6].
Concentrations of IaIp in plasma samples were measured with
a quantitative competitive enzyme linked immunoassay with a
monoclonal antibody against human IaIp (MAb 69.26) as previously
described [4]. All the samples were analyzed in a blinded fashion.
The non-parametric Mann-Whitney test (GraphPad version 4) was
used for statistical evaluation of the IaIp concentrations in the
respective groups of patients. Analyses of correlations were done with
the Spearman’s rho test using SPSS version 11.0.1.
Results
Patient’s characteristics
In order to exclude patients with clinical picture similar to
DENV of other aetiology, the criteria for patient selection was
confirmation of DENV infection by demonstrating viral RNA in
the D0 samples and complete sampling procedure, i.e. availability
of plasma samples from D0, D7 and D30. Based on these criteria,
33 patients were selected to measure the levels of IaIp out of the
200 patients included in the cohort study (Table 1). The cohort
consisted of 14 males, 19 females and the median age of the
patients was 8 years (range 3–14 years). Seven patients were
classified with DF, 15 with DHF, and 11 with DSS according to
the WHO criteria [7]. Based on the serological profile of the
patients (IgM/IgG ratio) 5 patients could be classified as primary
DENV infections whereas the remaining 28 patients had a
secondary DENV infection. DENV 1 and 3 were the predominant
serotypes (n = 14 and n= 13, respectively), while DENV-2 and
DENV-4 were only detected in a few patients (n = 4 and n= 2
respectively), suggesting that all four serotypes of DENV were
circulating in Semarang at the time of sampling.
Concentration of IaIp in acute viral infections
First, we measured IaIp levels in healthy young children to
establish baseline level (median 393 mg/ml, range 236–658 mg/ml)
in the study population (Figure 1). Next, we measured the levels of
this molecule in plasma from patients with acute systemic (DENV)
and non-systemic (RSV) viral infections upon hospital admission.
Patients of both groups required hospitalization, indicating that
these infections were severe. Both the DENV (median 165, range
56–281 mg/ml) and RSV (median 217, range 145–553 mg/ml)
patient groups had significantly lower levels of IaIp on D0
compared to the healthy control group (P,0.0001 and P,0.0001
respectively).
Concentration of IaIp in DENV infections correlate with
disease severity
Several mediators involved in hemostasis have been associated
with DENV-associated disease severity. Therefore, we sought to
investigate the association of IaIp concentration with development
of DHF and/or DSS. Patients experiencing mild DF, had similar
levels of IaIp as patients with acute RSV (D0 median 202, range
109–261mg/ml, P= 0.5867). It is worth noting that the patient in
this group, with the lowest concentration of IaIp was classified with
‘‘severe DF’’ i.e. experienced hemorrhagic manifestations but did
not meet all criteria of WHO to be classified as DHF grade I-IV.
Patients experiencing hemorrhagic fever (DHF grades I-IV) had
Table 1. Characteristics of patients included in the study.
Characteristics
DF patients
n =7
DHF patients
n=15
DSS patients
n =11
RSV patients
n=12
Healthy controls
n =37
Age range (median) 3–14 (12) years 4–13 (10) years 5–12 (6) years 2–6 (4) months 3–6 (4.3) years
Gender, (male n) 4 6 4 7 19
Origin Indonesia Indonesia Indonesia The Netherlands Indonesia
Duration of fever range (median) 2–4 (3) days 3–6 (4) days 2–5 (4) days 1–5 (3) days n.a.
Hematocryte % range (median)* 33–43 (37.8) 33–53 (39.3) 32–51 (41) n.a. n.a.
Platelet count cells x 103/mm3 * (median) 57–186 (106) 14–207 (66) 10–90 (43) n.a. n.a.
Albumin g/l range (median) * 2.0–4.2 (3.7) 1.9–4.3 (3.60 1.0–3.8 (3.2) n.a. n.a.
AT III % range (median) * 51–110 (85) 75–120 (97) 50–110 (51) n.a. n.a.
APTT sec range (median) * 39–76 (48) 38–84 (53) 49–120 (68) n.a. n.a.
*on time of admission.
n.a.: not applicable.
doi:10.1371/journal.pone.0009967.t001
Figure 1. Concentration of IaIp in patients with varying DENV
disease severity (day of admission to the hospital) and in
healthy controls (hc). *: statistically significant differences with the
Mann-Whitney test. Straight lines represent the median.
doi:10.1371/journal.pone.0009967.g001
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significantly lower levels of IaIp on D0, compared to patients with
mild DF (median 151, range 56–281 mg/ml, P= 0.0443), whereas
patients with DSS had the lowest levels of IaIp (median 112, range
56–208 mg/ml) compared to DF, DHF-I/II, and RSV groups
(P = 0.0028, P = 0.0461, P= 0.0006 respectively). As shown in
figure 2, clinical recovery of DHF patients (grades I–IV) was
associated with a rapid and significant increase of IaIp within
seven days post admission (median 261, range 152–434 mg/ml,
P,0.0001). By D30 of follow up the levels of IaIp between patients
recovering from DF (median 282, range 236–414 mg/ml), and
DHF grades I–IV (median 283, range 179–414 mg/ml) were
similar (P = 0.6066), but lower than the level of IaIp in patients
recovering from RSV (median 333; range 205–462 mg/ml).
However, the concentrations did not reach levels measured in
the healthy controls (P,0.0001), suggesting different normaliza-
tion kinetics of this molecule during DENV infections compared to
RSV infection.
Clinical records and laboratory findings from the day of
admission of the DENV infected patients were used to look for
association of IaIp and clinical and laboratory markers of disease
severity (Table 2). Circulating concentrations of IaIp correlated
inversely with disease severity (P = 0.041), ascites (P = 0.010), and
activated partial thromboplastin time (aPTT, P= 0.001). In
addition there was a correlation of IaIp with thrombocytopenia
(P = 0.002), anti-thrombin III (ATIII, P = 0.024) and albumin
levels (P = 0.018).
Discussion
This study is the first one to demonstrate that IaIp is
significantly decreased during acute viral infections. Our data
showed that both a systemic (DENV) and a localized (RSV) viral
infection can affect the concentration of IaIp, with a more
pronounced effect measured in patients with DSS. Several studies
have shown that mediators and other soluble factors (including
antibodies and cytokines) differ significantly between DHF and
DSS groups [8–10].
Plasma levels of IaIp have been shown to be reduced in
neonatal and adult bacterial-induced sepsis and the levels correlate
inversely with mortality in adult patients with sepsis, prompting
investigation of its potential as a prognostic or diagnostic marker
[3,4] as well as its therapeutic potential for sepsis and anthrax
intoxication [11,12]. Fatal outcome of DSS can be significantly
reduced when timely supportive treatment and plasma replace-
ment is given to the patients. In this respect, a biomarker with
diagnostic/prognostic potential is of paramount importance to
assist supportive treatment. In this study we report significant
correlations of IaIp and several markers of DENV disease severity,
especially thrombocytopenia, a hallmark of severe DENV induced
disease (Table 2). These data warrant further studies, designed to
elucidate the prognostic potential of IaIp. In this study, we
investigated the plasma levels of IaIp in patients that were severely
ill and required hospitalization. Studies should be designed in the
future to include infected patients prospectively in order to
understand the kinetics and prognostic value of IaIp in the early
stages of disease (during fever). In light of the therapeutic value of
IaIp in sepsis, the potential of this molecule for treatment of DSS
should be explored.
The pathogenesis of DENV infections is poorly understood
although several studies have concluded that soluble factors and
mediators are implicated in the development of DHF/DSS. The
significantly decreased concentrations of IaIp in patients with
severe disease, in particular in DSS patients, could explain several
pathological phenomena seen in DSS. First, the heavy chains of
IaIp molecules are known to inhibit activation of both the
alternative and classical pathways of the complement system, both
in vitro and in vivo [13]. In this respect, low levels of IaIp could result
in the increased levels of C5a often seen in DHF/DSS patients
[14]. Second, IaIp inhibit plasmin via its light chain bikunin [2].
Plasmin has a major role in the fibrinolytic system, as an enzyme
that degrades fibrin. Impaired fibrinolysis is a hallmark of DSS
[10]. In this report, IaIp levels were found to be associated with
coagulation (aPTT) and anti-coagulation (ATIII) factors (Table 2),
however more studies are needed in order to elucidate the possible
role of IaIp in the pathogenesis of DENV infections. Third, IaIp
are synthesized and assembled in the liver and low plasma levels of
these molecules may reflect liver involvement.
Taken together, this is the first study to highlight the importance
of IaIp in acute viral infections and provide an incentive to study
the diagnostic and prognostic role of IaIp during acute DENV
infections. Our cohort was carefully chosen to include only
patients with confirmed DENV infection as demonstrated by the
Figure 2. Concentration of IaIp in DENV infected patients with
varying disease severity on different time points after
infection. Data are depicted as mean 6 standard deviation.
doi:10.1371/journal.pone.0009967.g002
Table 2. Correlation of IaIp with clinical and laboratory markers of DENV disease severity measured on day of admission.
Spearman’s rho IaIp severity Pleural effusion ascites Platelet count Hematocryte ATIII (%) aPTT (sec) Albumin (g/l)
Correlation coefficient 20.357 20.248 20.443 0.514 0.03913 0.492 20.617 0.415
P value 0.041 0.163 0.010 0.002 0.8289 0.024 0.001 0.018
N 33 33 33 33 33 21 25 32
Significant P values are underlined.
ATIII: anti-thrombin III, aPTT: activated partial thromboplastin time.
doi:10.1371/journal.pone.0009967.t002
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presence of viral RNA in acute phase plasma of the patients. Since
little is known about the epidemiology of other viral infections in
that region with similar clinical presentation to dengue, we chose
to study only the subjects from which DENV viral RNA could be
recovered. As a result, our cohort was rather small and therefore
other relevant questions such as correlation of IaIp levels and
primary or secondary DENV infections could not be addressed.
Determination of IaIp concentrations in larger cohorts of patients
with different genetic backgrounds, in combination with measure-
ment of other biological markers, such as liver enzymes, are
necessary to better understand the role of IaIp in the pathogenesis
of DENV infections. Studies are ongoing to address these issues.
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